Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
25 May 2023 - 7:00AM
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology
company that aims to develop the world’s most potent vaccines,
today announced that the Compensation Committee of the company’s
Board of Directors granted two employees nonqualified stock options
to purchase an aggregate of 31,000 shares of its common stock with
an exercise price of $1.96, which is equal to the closing price of
Gritstone’s common stock on May 16, 2023, the date of the grant.
These stock options are part of an inducement material to the new
employees becoming an employee of Gritstone, in accordance with
Nasdaq Listing Rule 5635(c)(4).
The stock options will vest over a four-year period, with 25% of
the options vesting on the first anniversary of the employees’ date
of hire, and 1/48th of the options vesting monthly thereafter,
subject to the employees’ continued employment with Gritstone on
such vesting dates. The stock options are subject to the terms and
conditions of Gritstone’s 2021 Employment Inducement Incentive
Award Plan and the stock option agreement covering the grant.
About Gritstone bioGritstone bio, Inc. (Nasdaq:
GRTS) is a clinical-stage biotechnology company that aims to
develop the world’s most potent vaccines. We leverage our
innovative vectors and payloads to train multiple arms of the
immune system to attack critical disease targets. Independently and
with our collaborators, we are advancing a portfolio of product
candidates to treat and prevent viral diseases and solid tumors in
pursuit of improving patient outcomes and eliminating disease.
www.gritstonebio.com
Gritstone bio ContactsInvestors:George E.
MacDougallDirector, Investor Relations & Corp CommsGritstone
bio, Inc.ir@gritstone.com
Media:Dan Budwick1AB(973) 271-6085dan@1abmedia.com
Gritstone bio (NASDAQ:GRTS)
Historical Stock Chart
From Apr 2024 to May 2024
Gritstone bio (NASDAQ:GRTS)
Historical Stock Chart
From May 2023 to May 2024